Topic: pharma

Novartis experienced a significant 10% drop in its stock price following the failure of its del-desiran drug in a late-stage trial, marking a troubling trend with three drug trial setbacks in just one week. This decline positions Novartis for its worst trading day on record, raising concerns among investors about the company's pipeline and future prospects.

Novo Nordisk's shares fell over 5% following disappointing guidance for 2026, despite reporting a rise in second-quarter sales and operating profit. This shift in outlook raises concerns about the company's future performance in the competitive GLP-1 drug market.